source
- LifeMine Therapeutics secures $263 million to develop safer transplant immunosuppressantLifeMine Therapeutics announced it has raised a total of $263 million through two venture financing rounds. The capital, which includes a newly disclosed $75 million Series D round, will be used t…
- Tenax Therapeutics to Release Phase 3 Heart Failure Trial Results SoonTenax Therapeutics announced that it will soon disclose data from its Phase 3 trial of a heart-failure treatment. The study is being watched as one of the largest binary events left for biotech st…